{"id":"NCT02474069","sponsor":"Novartis Pharmaceuticals","briefTitle":"Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis","officialTitle":"A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of 16 Weeks Secukinumab Dosage Interval Shortening in Comparison to Continued Standard Treatment (4-weekly 300 mg s.c.) in Patients With Moderate-severe Plaque Type Psoriasis Who Achieved Less Than Almost Clear Skin After 16 Weeks Under the Standard Dose of Secukinumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-08","primaryCompletion":"2016-09-15","completion":"2016-09-15","firstPosted":"2015-06-17","resultsPosted":"2019-07-05","lastUpdate":"2019-07-05"},"enrollment":772,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Plaque-type Psoriasis"],"interventions":[{"type":"DRUG","name":"Secukinumab","otherNames":[]}],"arms":[{"label":"Secukinumab Interval Shortening","type":"ACTIVE_COMPARATOR"},{"label":"Secukinumab 4-weekly","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.","primaryOutcome":{"measure":"Number of Participants With PASI 90 Response at Week 32","timeFrame":"at 32 weeks","effectByArm":[{"arm":"CDP - Secukinumab 300 mg s.c. (4-weekly)","deltaMin":93,"sd":null},{"arm":"CDP - Secukinumab 300 mg s.c. (2-weekly)","deltaMin":105,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.087"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":89,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":772},"commonTop":["NASOPHARYNGITIS","HEADACHE","DIARRHOEA","FATIGUE","PRURITUS"]}}